Matthew Barcus
Stock Analyst at Chardan Capital
(2.47)
# 2,417
Out of 5,240 analysts
21
Total ratings
25%
Success rate
34.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $4.86 | +105.76% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $27.05 | -0.18% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $98 | $8.77 | +1,017.45% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $28.80 | +11.11% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $2,200 | $3.87 | +56,747.55% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.86 | +214.69% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $22.10 | -63.80% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $4.86
Upside: +105.76%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $27.05
Upside: -0.18%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $98
Current: $8.77
Upside: +1,017.45%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $28.80
Upside: +11.11%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $2,200
Current: $3.87
Upside: +56,747.55%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.86
Upside: +214.69%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $22.10
Upside: -63.80%